NCT04428554招募中2 期
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 130
- 试验地点
- 33
- 主要终点
- Overall Survival
研究概览
简要总结
This is a Phase II, multicenter, randomized open-label and comparative study that has been designed to evaluate whether local consolidative radiotherapy in addition to standard of care improves overall survival as compared with standard of care in patients with regional and/or distant metastatic urothelial bladder cancer who have no disease progression and with no more than three residual distant metastatic lesions following the initial phase of first-line systemic therapy.
Each patient will be followed during 4 years from the date of randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Urothelial bladder cancer histologically proven (both pure urothelial cancers and mixed histologic features are allowed)
- •Metastatic patients to regional nodes (Tx,N1-N3,M0) and/or distant sites (Tx,Nx,M1a-M1b) documented with contrast-enhanced CT-scanner of the chest, abdomen and pelvis, either de novo or presenting first regional/distant relapse following cystectomy (with no local recurrence in the cystectomy bed)
- •Completion of the initial phase (4-6 cycles) of 1st line metastatic treatment (systemic therapy by chemotherapy and/or immunotherapy by immune check-point inhibitor according to standard recommendations). Patients having started maintenance therapy are eligible.
- •No disease progression after the initial phase of first-line metastatic systemic therapy according to RECIST v1.1
- •No more than 3 residual distant metastatic lesions following the initial phase of first-line metastatic systemic therapy:
- •Regional nodes (below aortic bifurcation) are not included in the count of distant metastatic lesions
- •The number of distant residual lesions is determined on the basis of the imaging modality for tumor response assessment performed after systemic treatment according to local habits (CT-scan or 18FDG PET-CT if performed):
- •In case of response assessment by CT-scanner only: residual lesions are all remaining visible lesions In case of response assessment by additional 18FDG PET-CT: residual lesions are only the lesions with residual hyperfixation
- •Regarding distant lymph nodes metastases:
- •If evaluation is performed by CT-scanner only, residual lymph nodes are considered pathological according to one or several criteria among: Short axis ≥ 1cm/Central necrosis/Heterogeneous contrast enhancement
- •Residual para-aortic nodes involvement accounts for one lesion, even if several para-aortic nodes are involved.
- •Other nodes: each involved node accounts for one lesion.
- •Residual distant metastases (if applicable) eligible for SBRT in terms of dose constraints to the organs at risk, with no prior radiotherapy interfering with SBRT
- •8 weeks or less between last cycle of the initial phase of systemic treatment and randomization
- •No contraindication to pelvic radiotherapy
- •Signed informed consent
- •Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
- •Patient affiliated to a Social Health Insurance in France
排除标准
- •Non-transitional cell histology (Squamous cell carcinoma, adenocarcinoma or neuroendocrine carcinoma of the bladder)
- •Brain metastases before systemic treatment
- •Liver metastases before systemic treatment
- •Absence of target to be irradiated (i.e. previous cystectomy + no residual distant lesions following systemic treatment + no pelvic or para-aortic nodes at metastatic presentation)
- •Patient with relapse following definitive chemoradiation of the bladder
- •Local recurrence in the cystectomy bed following cystectomy
- •Previous pelvic irradiation
- •Prior radiotherapy near the residual metastatic lesions precluding ablative SBRT
- •Active inflammatory bowel disease
- •Contraindication to SBRT of a lesion due to organ dysfunction; in particular, patients with lung lesions and documented or suspected interstitial lung disease should not be included
- •History of scleroderma
- •Current or past history of second neoplasm diagnosed within the last 5 years (except basocellular carcinoma and prostate cancer incidentally discovered during previous cystoprostatetectomy and pelvic lymph node dissection and with a good prognosis [T stage <pT3b and Gleason <8 and pN- and post-operative PSA <0.1 ng/mL])
- •Pregnancy or breast feeding or inadequate contraceptive measures
- •Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- •Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
- •Concurrent enrolment in another interventional therapeutic clinical study
结局指标
主要结局
Overall Survival
时间窗: 4 years for each patient
次要结局
- Progression Free Survival(4 years for each patient)
- Quality of life will be evaluated by the EORTC QLQ-C-30 questionnaire(4 years for each patient)
- Safety will be assessed by the toxicity grading of the National Cancer Institute (NCI-CTCAE v5)(4 years for each patient)
研究者
研究点 (33)
Loading locations...
相似试验
Unknown
2 期
The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line TreatmentNon Small Cell Lung Cancer, OligometastaticNCT01796288Wu Jieping Medical Foundation200
招募中
2 期
Consolidative Prostate Radiotherapy in Metastatic Prostate CancerProstate MetastasesNCT05656794University Health Network, Toronto40
招募中
2 期
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPCRadiotherapyPancreatic CancerEnvafolimabCapecitabineNCT06202014Cancer Institute and Hospital, Chinese Academy of Medical Sciences43
招募中
2 期
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBMGlioblastomaNCT03008148Johnpro Biotech, Inc.288
招募中
2 期
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPCancer of ProstateNCT03899077Cancer Research Antwerp202